Autoimmune myositis—Mechanism and therapy development

Uruha, Akinori

doi:10.1111/ncn3.12563

Cited by 3 publications

(2 citation statements)

References 135 publications

(321 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,4 Over the past few decades, an association between respective myositis-specific autoantibodies and clinicopathological features was revealed. 5 However, the correlation between the clinico-patholo-serological features and genetic background remains unclear and needs to be investigated in greater detail together with elucidating associated pathogenic factors.…”

Section: Introductionmentioning

confidence: 99%

“…Mainly based upon the clinicopathological and serological features, AIM is now divided into four major subcategories: immune‐mediated necrotizing myopathy (IMNM), dermatomyositis (DM), antisynthetase syndrome (ASS), and inclusion body myositis (IBM) 2,4 . Over the past few decades, an association between respective myositis‐specific autoantibodies and clinicopathological features was revealed 5 . However, the correlation between the clinico‐patholo‐serological features and genetic background remains unclear and needs to be investigated in greater detail together with elucidating associated pathogenic factors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of immune‐mediated necrotizing myopathy withHLApolymorphisms

Ohnuki

Suzuki

Uruha

et al. 2023

HLA

Self Cite

View full text Add to dashboard Cite

Immune‐mediated necrotizing myopathy (IMNM) is a type of autoimmune myositis typically characterized clinically by proximal muscle weakness with elevated creatine kinase levels, pathologically by myofiber necrosis and regeneration with paucity of lymphocytic cell infiltration, and serologically by the presence of either of two myositis‐specific autoantibodies, anti‐SRP, and anti‐HMGCR antibodies. However, the HLA loci and alleles associated with IMNM are still not fully understood at least partly because IMNM was a relatively recently established condition. In this study, we genotyped the six HLA loci (HLA‐A, ‐B, ‐C, ‐DRB1, ‐DQB1 and ‐DPB1) in 250 patients (237 patients over age 18 years and 13 juvenile patients) diagnosed with IMNM based on clinicopathological features and autoantibody information and performed a case control study with Japanese healthy subjects. In the adult patients, specific HLA alleles associated with IMNM were identified at all HLA loci, with DRB1*08:03 showing the strongest association (OR = 2.5; p = 0.00000017). Furthermore, subgroup analysis with various clinical information showed that C*03:04 (OR = 3.7; p = 0.00012) was a higher risk allele for collagen disease in adult patients, and B*13:01 (OR = 23.2; p = 0.021) and C*03:04 (OR = 5.8; p = 0.0074) were higher risk for juvenile patients with anti‐HMGCR antibody‐positive IMNM. These findings will help to better understand the HLA genetic background and features of IMNM in designing future studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Association of immune‐mediated necrotizing myopathy withHLApolymorphisms

Ohnuki

Suzuki

Uruha

et al. 2023

HLA

Self Cite

View full text Add to dashboard Cite

show abstract

Pathologic Features of Anti-Ku Myositis

Oyama,

Holzer,

Ohnuki

et al. 2024

Neurology

View full text Add to dashboard Cite

Association Between HLA Alleles and Autoantibodies in Dermatomyositis Defined by Sarcoplasmic Expression of Myxovirus Resistance Protein A

et al. 2023

View full text Add to dashboard Cite

ObjectiveThe diagnosis in the studies analyzing human leucocyte antigen (HLA) of dermatomyositis was based on a combined clinical category of polymyositis/dermatomyositis. This retrospective study investigated the associations of HLA with five dermatomyositis-specific autoantibodies in Japanese patients diagnosed by muscle pathology.MethodsWe diagnosed Japanese patients with dermatomyositis based on sarcoplasmic expression of myxovirus resistance protein A. These patients underwent investigation for five dermatomyositis-specific autoantibodies and HLA genotyping.ResultsOf 175 patients (M:F=83:92; range 1–86 years; mean 46 years), 173 (98.9%) had one of the five autoantibodies. Seven alleles—A*02:07, B*46:01, DRB1*04:07, DRB1*07:01, DRB1*08:03, DQB1*06:01,andDPB1*02:02— were more frequently detected in the patients with dermatomyositis than healthy controls, but these associations were not significant after multiple testing correction. Stratifying by dermatomyositis-specific autoantibodies, we found the associations of already known six and new seven alleles—B*48:01, B*52:01, C*12:02, DRB1*04:05, DRB1*15:02, DPB1*05:01,andDPB1*09:01— with subsets of dermatomyositis. Moreover, significant associations of five alleles with anti-nucleosome remodeling deacetylase complex (Mi-2) remained after multiple testing correction. In particular, theDRB1*04:07(OR=28.9, correctedp=2.7×10-6) andDQB1*06:01(OR=4.0, correctedp=1.6×10-4) alleles were significantly more prevalent in patients with anti-Mi-2 antibody than in controls.ConclusionThis study demonstrated dermatomyositis-specific autoantibodies defined immunogenetic subsets of dermatomyositis.

show abstract

Autoimmune myositis—Mechanism and therapy development

Cited by 3 publications

References 135 publications

Association of immune‐mediated necrotizing myopathy withHLApolymorphisms

Association of immune‐mediated necrotizing myopathy withHLApolymorphisms

Pathologic Features of Anti-Ku Myositis

Association Between HLA Alleles and Autoantibodies in Dermatomyositis Defined by Sarcoplasmic Expression of Myxovirus Resistance Protein A

Contact Info

Product

Resources

About